Increased expression and activation of matrix metalloproteinase-2 (MMP-2) in O-1N: Hamster oral squamous cell carcinoma with high potential lymph node metastasis

Journal of Experimental and Clinical Cancer Research

Volumn 25, Issue 3, 2006, Pages 417-423

  Zhang, Y ^a,b   Wang, C ^b   Mizukami, H ^a   Itoh, H ^a   Kusama, M ^a   Ozawa, K ^a   Jinbu, Yoshinori ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Lymph node; Matrix metalloproteinase 2; Metastasis; Oral squamous cell carcinoma

Indexed keywords

GELATINASE A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER TRANSPLANTATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMSTER; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CRICETINAE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MESOCRICETUS; MOUTH NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33751085878     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Myoung H., Kim M.J., Hong S.D., Lee J.I., Lim C.Y., Hong S.P.: Expression of membrane type I-matrix metalloproteinase in oral squamous cell carcinoma. Cancer Lett. 185:201-209, 2002.
2. Kudo Y., Kitajima S., Ogawa I. et al.: Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin. Cancer Res. 10:5455-5463, 2004.
3. Liotta L.A., Kohn E.G.: The microenvironment of the tumour-host interface. Nature 411:375-379, 2001.
4. Sheu B.C., Lien H.C., Ho H.N. et al.: Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res. 63:6537-6542, 2003.
5. Kawata R., Shimada T., Maruyama S., Hisa Y., Takenaka H., Murakami Y.: Enhanced production of matrix metalloproteinase-2 in human head and neck carcinoma is correlated with lymph node metastasis. Acta Otolaryngol. 122:101-106, 2002.
6. Nakamura H., Ueno H., Yamashita K. et al.: Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res. 59:467-473, 1999.
7. Garbisa S., Scagliotti G., Masiero L. et al.: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res. 52:4548-4549, 1992.
8. Gohji K., Fujimoto N., Hara I. et al.: Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. Int. J. Cancer. 79:96-101, )998.
9. Sheen-Chen S.M., Chen H.S., Eng H.L., Sheen C.C., Chen W.J.: Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett.: 173:79-82, 2001.
10. Leppa S., Saarto T., Vehmanen L., Blomqvist C., Elomaa I.: A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. 10:1057-1063, 2004.
11. Hong S.D., Hong S.P., Lee J.I., Lim C.Y.: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 236:207-213, 2000.
12. Yoshizaki T., Maruyama Y., Sato H., Furukawa M.: Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma. Int. J. Cancer 95:44-50, 2001.
13. Chavey C., Mari B., Monthouel M.N., Bonnafous S. et al.: Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 278:11888-11896, 2003.
14. Mills J.C., Syder A.J., Hong C.V., Guruge J.L., Raaii F., Gordon J.I.: A molecular profile of the mouse gastric parietal cell with and without exposure to Helicobacter pylori. Proc. Natl Acad. Sci. USA 98:13687-13692, 2001.
15. Wang J., Xi L., Hunt J.L. et al.: Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 64:1861-1866, 2004.
16. Ohtake K., Shingaki S., Nakajima T.: Histologic study on the metastatic process in the experimental model of lymph node metastasis. Oral Surg. Oral Med. Oral Pathol. 75:472-478, 1993.
17. Oda Y., Cheng J., Nakajima T., Saku T.: Expression of adhesion molecules in the vascular invasion process of O-1N, hamster squamous cell carcinoma with high potential of lymph node metastasis. Oral Med. Pathol.: 7:9-18, 2002.
18. Franchi A., Santucci M., Masini E., Sardi I., Paglierani M., Gallo O.: Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 95:1902-1910, 2002.
19. Fang J., Shing Y., Wiederschain D. et al.: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a rumor model. Proc. Natl Acad. Sci. USA 97:3884-3889, 2000.
20. Ito A., Mukaiyama A., Itoh Y. et al.: Degradation of interleukin 1beta by matrix metalloproteinases. J. Biol. Chem. 271:14657-14660, 1996.
21. Moss M.L., Jin S.L., Milla M.E., Bickett D.M., Burkhart W., Carter HL et al.: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736, 1997.
22. Tsai C.H., Hsieh Y.S., Yang S.F., Chou M.Y., Chang Y.C.: Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in human oral squamous cell carcinoma and the effect of protein kinase C inhibitors: preliminary observations. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 95:710-716, 2003.
23. Kusukawa J., Sasaguri Y., Shima I., Kameyama T., Morimatsu M.: Expression of matrix metalloproteinase-2 related to lymph node metastasis of oral squamous cell carcinoma. A clinico-pathologic study. Am. J. Clin. Pathol. 99:18-23, 1993.
24. Sutinen M., Kainulainen T., Hurskainen T. et al.: Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br. J. Cancer 77:2239-2245, 1998.
25. Zucker S., Cao J., Chen W.T.: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-6650, 2000.
26. Eccles S.A., Box G.M., Court W.J. et al.: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20:749-755, 1999.
27. Bergers G., Javaherian K., Lo K.M., Folkman J., Hanahan D.: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812, 1999.
28. Yamamoto A., Yano S., Shiraga M. et al.: A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int. J. Cancer. 103:822-828, 2003.
29. Patel B.P., Shah P.M., Rawal U.M. et al.: Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J. Surg. Oncol. 90:81-88, 2005